title: Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma.
abstract: OBJECTIVE
  To examine families ascertained for late-onset primary open-angle glaucoma (POAG) to determine mutations in the gene coding for myocilin.
  
  
  METHODS
  The diagnosis of late-onset POAG was defined as age at diagnosis more than 35 years, intraocular pressure (IOP) 22 mm Hg or more in both eyes or 19 mm Hg or more while the patient was taking two glaucoma medications, glaucomatous optic neuropathy in both eyes, and visual field loss consistent with optic nerve damage in at least one eye of the proband. Two of three criteria were required in other family members. DNA from all families was screened for polymorphisms in myocilin using single-strand conformation polymorphism analysis. All polymorphisms were sequenced for mutations.
  
  
  RESULTS
  Eighty-three affected people in 29 families with late-onset POAG were screened for mutations. Three mutations, two novel missense (Thr377Met and Glu352Lys) and one nonsense (Gln368STOP), were identified. The missense mutations did not segregate with the disease phenotype in these families. The nonsense mutation was found in 3 of 29 unrelated families with POAG. All affected family members and 8 of 12 in whom glaucoma was suspected had the Gln368STOP mutation. All people with this mutation had elevated IOP, and 78% had POAG by age 70.
  
  
  CONCLUSIONS
  Three mutations were identified in the gene coding for myocilin in families with late-onset POAG. Of these, the Gln368STOP mutation was highly associated with the development of glaucoma. All people with this mutation had glaucoma or elevated IOP by age 70. In the United States, the Gln368STOP mutation in myocilin is strongly associated with the development of late-onset POAG. However, factors in addition to the presence of this mutation seem to play a role in the development of ocular hypertension and glaucoma in these families.
authors.affiliation: Duke University Medical Center, Durham, North Carolina, USA.
authors.forename: R R
authors.initials: RR
authors.lastname: Allingham
authors.forename: J L
authors.initials: JL
authors.lastname: Wiggs
authors.forename: M A
authors.initials: MA
authors.lastname: De La Paz
authors.forename: D
authors.initials: D
authors.lastname: Vollrath
authors.forename: D A
authors.initials: DA
authors.lastname: Tallett
authors.forename: B
authors.initials: B
authors.lastname: Broomer
authors.forename: K H
authors.initials: KH
authors.lastname: Jones
authors.forename: E A
authors.initials: EA
authors.lastname: Del Bono
authors.forename: J
authors.initials: J
authors.lastname: Kern
authors.forename: K
authors.initials: K
authors.lastname: Patterson
authors.forename: J L
authors.initials: JL
authors.lastname: Haines
authors.forename: M A
authors.initials: MA
authors.lastname: Pericak-Vance
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018388:Codon, Terminator / Q000235:genetics; D003598:Cytoskeletal Proteins; D004252:DNA Mutational Analysis; D017931:DNA Primers / Q000737:chemistry; D005136:Eye Proteins / Q000235:genetics*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000235:genetics* / Q000473:pathology; D005973:Glutamine / Q000235:genetics; D006023:Glycoproteins / Q000235:genetics*; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009898:Optic Disk / Q000473:pathology; D009901:Optic Nerve Diseases / Q000473:pathology; D010375:Pedigree; D017354:Point Mutation; D011110:Polymorphism, Genetic; D018807:Polymorphism, Single-Stranded Conformational; D014794:Visual Fields; D000099179:Myocilin
chemical_list: D018388:Codon, Terminator; D003598:Cytoskeletal Proteins; D017931:DNA Primers; D005136:Eye Proteins; D005973:Glutamine; D006023:Glycoproteins; D000099179:Myocilin